5-hydroxytryptophan has been researched along with Disease Exacerbation in 3 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignancies worldwide." | 5.46 | Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma. ( Cheng, J; Gao, X; Hou, X; Jin, H; Lv, J; Zheng, G, 2017) |
| "Lymph node metastasis is the leading cause of death in ESCC patients." | 5.46 | Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma. ( Cheng, J; Gao, X; Hou, X; Jin, H; Lv, J; Zheng, G, 2017) |
| "Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignancies worldwide." | 1.46 | Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma. ( Cheng, J; Gao, X; Hou, X; Jin, H; Lv, J; Zheng, G, 2017) |
| "Lymph node metastasis is the leading cause of death in ESCC patients." | 1.46 | Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma. ( Cheng, J; Gao, X; Hou, X; Jin, H; Lv, J; Zheng, G, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J | 1 |
| Jin, H | 1 |
| Hou, X | 1 |
| Lv, J | 1 |
| Gao, X | 1 |
| Zheng, G | 1 |
| Li, X | 1 |
| Wu, X | 1 |
| Ma, Y | 1 |
| Hao, Z | 1 |
| Chen, S | 1 |
| Fu, T | 1 |
| Chen, H | 1 |
| Wang, H | 1 |
| Carlbom, L | 1 |
| Espes, D | 1 |
| Lubberink, M | 1 |
| Martinell, M | 1 |
| Johansson, L | 1 |
| Ahlström, H | 1 |
| Carlsson, PO | 1 |
| Korsgren, O | 1 |
| Eriksson, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes[NCT02967354] | 39 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Uptake of tracer with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release (NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | % of injected dose (Mean) |
|---|---|
| Healthy Control | 0.17 |
| Obese With Oral Antidiabetic Drugs | 0.21 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 0.20 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 0.23 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 0.15 |
(NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | % of liver volume (Mean) |
|---|---|
| Healthy Control | 5.30 |
| Obese With Oral Antidiabetic Drugs | 14.40 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 13.42 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 5.50 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 9.01 |
(NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | % of pancreatic volume (Mean) |
|---|---|
| Healthy Control | 11.33 |
| Obese With Oral Antidiabetic Drugs | 11.54 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 8.75 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 9.58 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 9.72 |
Uptake of radioactive water with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release (NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | ml/min (Mean) |
|---|---|
| Healthy Control | 84.37 |
| Obese With Oral Antidiabetic Drugs | 134.90 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 107.72 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 72.20 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 59.82 |
(NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | cm^3 (Mean) |
|---|---|
| Healthy Control | 67.68 |
| Obese With Oral Antidiabetic Drugs | 88.54 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 98.96 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 64.1 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 53.39 |
3 other studies available for 5-hydroxytryptophan and Disease Exacerbation
| Article | Year |
|---|---|
Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma.
Topics: 5-Hydroxytryptophan; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Diseas | 2017 |
Oral administration of 5-hydroxytryptophan aggravated periodontitis-induced alveolar bone loss in rats.
Topics: 5-Hydroxytryptophan; Administration, Oral; Alveolar Bone Loss; Animals; Disease Progression; Enzyme- | 2015 |
[
Topics: 5-Hydroxytryptophan; Aged; Arginine; Blood Glucose; C-Peptide; Carbon Radioisotopes; Case-Control St | 2017 |